fluorouracil has been researched along with Bone Marrow Diseases in 62 studies
Fluorouracil: A pyrimidine analog that is an antineoplastic antimetabolite. It interferes with DNA synthesis by blocking the THYMIDYLATE SYNTHETASE conversion of deoxyuridylic acid to thymidylic acid.
5-fluorouracil : A nucleobase analogue that is uracil in which the hydrogen at position 5 is replaced by fluorine. It is an antineoplastic agent which acts as an antimetabolite - following conversion to the active deoxynucleotide, it inhibits DNA synthesis (by blocking the conversion of deoxyuridylic acid to thymidylic acid by the cellular enzyme thymidylate synthetase) and so slows tumour growth.
Bone Marrow Diseases: Diseases involving the BONE MARROW.
| Excerpt | Relevance | Reference |
|---|---|---|
| "Based upon the hypothesis that dipyridamole would potentiate the cytotoxicity of mitoxantrone and the combination of 5-fluorouracil (5-FU) and leukovorin, we performed a phase I/II trial of the combination of dipyridamole, 5-FU, leukovorin, and mitoxantrone in patients with metastatic breast cancer." | 9.07 | Phase I/II trial of dipyridamole, 5-fluorouracil, leukovorin, and mitoxantrone in metastatic breast cancer. ( Budd, GT; Bukowski, RM; Herzog, P, 1994) |
| "To review available data and implications for nurses of combination regimens containing capecitabine for metastatic breast cancer." | 8.85 | Capecitabine-based combination therapy for breast cancer: implications for nurses. ( Frye, DK, 2009) |
| "After intraperitoneal administration of carboplatin, each measured characteristics of bone marrow function was more significantly suppressed and the induced neutropenia was more serious in db/db mice than in the controls." | 7.81 | Myelotoxicity of carboplatin is increased in vivo in db/db mice, the animal model of obesity-associated diabetes mellitus. ( Aradi, J; Benkő, I; Géresi, K; Megyeri, A; Németh, J; Szabó, B; Szabó, Z, 2015) |
| "We report an update of our results of a trial of high-dose folinic acid (HDFA) and 5-fluorouracil (5-FU) in advanced breast cancer." | 7.67 | 5-Fluorouracil and high-dose folinic acid as salvage treatment of advanced breast cancer: an update. ( Gorni, F; Marini, G; Marpicati, P; Simoncini, E; Zambruni, A; Zaniboni, A, 1987) |
| "Diarrhea is dose-limiting with weekly 5-fluorouracil (5-FU) plus high-dose leucovorin (LV)." | 5.09 | Phase I and pharmacokinetic study of weekly 5-fluorouracil administered with granulocyte-macrophage colony-stimulating factor and high-dose leucovorin: a potential role for growth factor as mucosal protectant. ( Blumenson, LE; Creaven, PJ; Frank, C; Meropol, NJ; Rustum, YM, 1999) |
| "Sixty-four consecutive patients with locally advanced (n = 7) or metastatic breast cancer (n = 57), were treated with a combination of laevofolinic acid 100 mg m-2 plus 5-fluorouracil 340 mg m-2 i." | 5.08 | Laevofolinic acid, 5-fluorouracil, cyclophosphamide and escalating doses of epirubicin with granulocyte colony-stimulating factor support in locally advanced and/or metastatic breast carcinoma: a phase I-II study of the Southern Italy Oncology Group (GOIM ( Agostara, B; Cariello, S; Colucci, G; Durini, E; Gebbia, V; Giotta, F; Pacilio, G; Pezzella, G; Romito, S; Testa, A, 1995) |
| "Based upon the hypothesis that dipyridamole would potentiate the cytotoxicity of mitoxantrone and the combination of 5-fluorouracil (5-FU) and leukovorin, we performed a phase I/II trial of the combination of dipyridamole, 5-FU, leukovorin, and mitoxantrone in patients with metastatic breast cancer." | 5.07 | Phase I/II trial of dipyridamole, 5-fluorouracil, leukovorin, and mitoxantrone in metastatic breast cancer. ( Budd, GT; Bukowski, RM; Herzog, P, 1994) |
| "Two consecutive studies were undertaken in patients with advanced adenocarcinoma of the ovary to compare melphalan, adriamycin and 5-fluorouracil (MAF) with cyclophosphamide, adriamycin and 5-fluorouracil (CAF)." | 5.05 | Triple drug chemotherapy for advanced ovarian carcinoma: comparative study of two regimens. ( Aroney, RS; Dalley, DN; Levi, JA, 1981) |
| "To review available data and implications for nurses of combination regimens containing capecitabine for metastatic breast cancer." | 4.85 | Capecitabine-based combination therapy for breast cancer: implications for nurses. ( Frye, DK, 2009) |
| " Until ongoing phase III trials confirm these benefits, the current standard treatment for metastatic pancreatic adenocarcinoma remains single agent gemcitabine." | 4.81 | A comprehensive update on the use of chemotherapy for metastatic pancreatic adenocarcinoma. ( Bruckner, HW; Kozuch, P; Petryk, M, 2002) |
| "After intraperitoneal administration of carboplatin, each measured characteristics of bone marrow function was more significantly suppressed and the induced neutropenia was more serious in db/db mice than in the controls." | 3.81 | Myelotoxicity of carboplatin is increased in vivo in db/db mice, the animal model of obesity-associated diabetes mellitus. ( Aradi, J; Benkő, I; Géresi, K; Megyeri, A; Németh, J; Szabó, B; Szabó, Z, 2015) |
| "The patients with local advanced and metastatic colorectal cancer, receiving fluorouracil-based chemotherapy, and with an average plasma concentration of fluorouracil between 25 - 35 mg/L have a better prognosis, and lower incidence of adverse reactions such as bone marrow suppression, mucositis and diarrhea." | 3.78 | [Role of pharmacokinetic monitoring of serum fluorouracil concentration in patients with local advanced and metastatic colorectal cancer and further improving efficacy of fluorouracil-based chemotherapy]. ( Cai, X; Gu, HL; Hu, J; Song, WF; Wang, LW; Xue, P; Yang, HY, 2012) |
| "Studies were carried out to determine whether the combination of IL-1 + M-CSF, similar to the effect of these cytokines on neutropenia, was able to reduce the duration of thrombocytopenia in the 5-fluorouracil (5-FU)-myelosuppressed mouse." | 3.69 | Enhanced platelet recovery in myelosuppressed mice treated with interleukin-1 and macrophage colony-stimulating factor: potential interactions with cytokines having megakaryocyte colony-stimulating activity. ( Evans, MJ; Johnke, RM; Kovacs, CJ; Powell, DS; Thomas-Patterson, D, 1996) |
| "7 mg/kg/d of dipyridamole, we examined the relationships between 5FUra dose and steady-state plasma concentration (Css) and the percentage reduction in WBCs, as well as the percentage frequency of stomatitis." | 3.68 | Pharmacokinetic and pharmacodynamic analysis of fluorouracil during 72-hour continuous infusion with and without dipyridamole. ( Egorin, MJ; Forrest, A; Remick, S; Trump, DL; Tutsch, KD; Willson, JK, 1991) |
| "We report an update of our results of a trial of high-dose folinic acid (HDFA) and 5-fluorouracil (5-FU) in advanced breast cancer." | 3.67 | 5-Fluorouracil and high-dose folinic acid as salvage treatment of advanced breast cancer: an update. ( Gorni, F; Marini, G; Marpicati, P; Simoncini, E; Zambruni, A; Zaniboni, A, 1987) |
| "Fourteen patients with stage II-IV breast cancer were enrolled in a phase II study of cyclophosphamide followed by PIXY321 as a means of mobilizing peripheral blood progenitor cells (PBPC)." | 2.68 | A phase II study of cyclophosphamide followed by PIXY321 as a means of mobilizing peripheral blood hematopoietic progenitor cells. ( Bitran, JD; Garrison, L; Hanauer, S; Johnson, L; Klein, L; Martinec, J; Proeschel, C; Roman-Unfer, S; Schroeder, L, 1996) |
| "Neoadjuvant RT for rectal cancer has lasting effects on the pelvic BM, which are demonstrable during adjuvant OxF." | 1.43 | Long-Term Bone Marrow Suppression During Postoperative Chemotherapy in Rectal Cancer Patients After Preoperative Chemoradiation Therapy. ( Baby, R; Chen, T; Jabbour, SK; Lu, SE; Moss, RA; Newman, NB; Nissenblatt, MJ; Sidhu, MK, 2016) |
| "Toxicity was acceptable, with grade 3 renal failure (n=1) and grade 3 or 4 myelotoxicity (n=2)." | 1.43 | Weekly Multi-agent Chemotherapy (CMF-b) for Advanced Non-melanoma Skin Cancer. ( Dietrich, PY; Espeli, V; Hottinger, AF; Modarressi, A; Ruegg, E, 2016) |
| "Lobaplatin plus 5-Fu combined with concurrent radiotherapy is safe and effective in treating patients with middle-advanced stage esophageal cancer." | 1.42 | Clinical Study on Lobaplatin Combined with 5-Fu and Concurrent Radiotherapy in Treating Patients with Inoperable Esophageal Cancer. ( Huang, JZ; Jia, XJ, 2015) |
| "The toxic effects of S-1 can lead to discontinuation of treatment." | 1.35 | Comparison of alternate-day versus consecutive-day treatment with S-1: assessment of tumor growth inhibition and toxicity reduction in gastric cancer cell lines in vitro and in vivo. ( Arai, W; Haruta, H; Hirashima, Y; Hosoya, Y; Hyodo, M; Kurashina, K; Nagai, H; Saito, S; Sakuma, K; Shirasaka, T; Yasuda, Y; Yokoyama, T; Zuiki, T, 2008) |
| "Haematopoietic colony-stimulating factors are used frequently to moderate myelotoxicity, but administration of granulocyte-colony-stimulating factor (G-CSF) prior to chemotherapy actually may worsen the toxic effects on bone marrow." | 1.33 | Effect of rosiglitazone, an insulin sensitizer, on myelotoxicity caused by repeated doses of 5-fluorouracil. ( Benko, I; Benko, K; Djazayeri, K; Rózsa, B; Szabó, B; Szentmiklósi, AJ; Szilvássy, Z, 2006) |
| "Eighty-four patients with advanced gastric cancer treated in four centres in Scotland between June 1980 and December 1982 were reviewed following treatment with 5-fluorouracil, adriamycin and mitomycin-C (FAM)." | 1.27 | Advanced gastric cancer: experience in Scotland using 5-fluorouracil, adriamycin and mitomycin-C. ( Allan, SG; Calman, KC; Carter, DC; Cunningham, D; Hutcheon, AW; Kaye, SB; McArdle, CS; Sangster, G; Smyth, JF; Soukop, M, 1984) |
| "Four hepatocellular cancer patients and 11 metastatic liver cancer patients were treated with intra-hepato-arterial infusions of cis-diamminedichloroplatinum (II) plus 5-fluorouracil." | 1.27 | Intra-hepato-arterial infusions of cis-diamminedichloroplatinum (II) and 5-fluorouracil clinically effective for malignant liver tumors. ( Koga, S; Maeta, M; Murakami, A; Wakatsuki, T; Yoshioka, H, 1985) |
| "Forty-three patients with metastatic breast cancer who had not received prior chemotherapy were divided into two groups on the basis of whether or not a bone marrow examination revealed tumor." | 1.26 | Bone marrow involvement in breast cancer: effect on response and tolerance to combination chemotherapy. ( Bull, JM; Ingle, JN; Simon, RM; Tormey, DC, 1977) |
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 23 (37.10) | 18.7374 |
| 1990's | 18 (29.03) | 18.2507 |
| 2000's | 11 (17.74) | 29.6817 |
| 2010's | 10 (16.13) | 24.3611 |
| 2020's | 0 (0.00) | 2.80 |
| Authors | Studies |
|---|---|
| Li, Y | 1 |
| Zhu, S | 2 |
| Zhang, Y | 2 |
| Liu, T | 1 |
| Su, L | 1 |
| Zhang, Q | 1 |
| Luo, Y | 1 |
| Cairo, M | 1 |
| Auperin, A | 1 |
| Perkins, SL | 1 |
| Pinkerton, R | 1 |
| Harrison, L | 1 |
| Goldman, S | 1 |
| Patte, C | 1 |
| Géresi, K | 1 |
| Megyeri, A | 1 |
| Szabó, B | 2 |
| Szabó, Z | 1 |
| Aradi, J | 1 |
| Németh, J | 1 |
| Benkő, I | 2 |
| Wang, S | 1 |
| Zheng, G | 1 |
| Tian, S | 1 |
| Shen, L | 1 |
| Pak, Y | 1 |
| Shen, Y | 1 |
| Qian, J | 1 |
| Jones, M | 1 |
| Chase, J | 1 |
| Brinkmeier, M | 1 |
| Xu, J | 1 |
| Weinberg, DN | 1 |
| Schira, J | 1 |
| Friedman, A | 1 |
| Malek, S | 1 |
| Grembecka, J | 1 |
| Cierpicki, T | 1 |
| Dou, Y | 1 |
| Camper, SA | 1 |
| Maillard, I | 1 |
| Jia, XJ | 1 |
| Huang, JZ | 1 |
| Newman, NB | 1 |
| Sidhu, MK | 1 |
| Baby, R | 1 |
| Moss, RA | 1 |
| Nissenblatt, MJ | 1 |
| Chen, T | 1 |
| Lu, SE | 1 |
| Jabbour, SK | 1 |
| Espeli, V | 1 |
| Ruegg, E | 1 |
| Hottinger, AF | 1 |
| Modarressi, A | 1 |
| Dietrich, PY | 1 |
| Gu, Y | 1 |
| Shu, Y | 1 |
| Xu, Q | 1 |
| Zhang, J | 1 |
| Xiang, D | 1 |
| Mao, W | 1 |
| Lu, H | 1 |
| Wu, M | 1 |
| Wang, Q | 1 |
| Yu, Y | 1 |
| Herbst, KD | 1 |
| Han, W | 1 |
| Arai, W | 1 |
| Hosoya, Y | 1 |
| Haruta, H | 1 |
| Kurashina, K | 1 |
| Saito, S | 1 |
| Hirashima, Y | 1 |
| Yokoyama, T | 1 |
| Zuiki, T | 1 |
| Sakuma, K | 1 |
| Hyodo, M | 1 |
| Yasuda, Y | 1 |
| Nagai, H | 1 |
| Shirasaka, T | 1 |
| Frye, DK | 1 |
| Ramachandran, S | 1 |
| Mandal, M | 1 |
| Cai, X | 1 |
| Xue, P | 1 |
| Song, WF | 1 |
| Hu, J | 1 |
| Gu, HL | 1 |
| Yang, HY | 1 |
| Wang, LW | 1 |
| Barnett, KT | 1 |
| Malafa, MP | 1 |
| Lorvidhaya, V | 1 |
| Chitapanarux, I | 1 |
| Sangruchi, S | 1 |
| Lertsanguansinchai, P | 1 |
| Kongthanarat, Y | 1 |
| Tangkaratt, S | 1 |
| Visetsiri, E | 1 |
| Djazayeri, K | 1 |
| Szilvássy, Z | 1 |
| Benko, K | 1 |
| Rózsa, B | 1 |
| Szentmiklósi, AJ | 1 |
| Hofer, M | 2 |
| Vacek, A | 2 |
| Holá, J | 2 |
| Weiterová, L | 2 |
| Streitová, D | 1 |
| Shin, JW | 1 |
| Lee, MM | 1 |
| Son, JY | 1 |
| Lee, NH | 1 |
| Cho, CK | 1 |
| Chung, WK | 1 |
| Cho, JH | 1 |
| Son, CG | 1 |
| Hainsworth, JD | 1 |
| Malcolm, A | 1 |
| Johnson, DH | 1 |
| Burnett, LS | 1 |
| Jones, HW | 1 |
| Greco, FA | 1 |
| Cunningham, D | 1 |
| Soukop, M | 1 |
| McArdle, CS | 1 |
| Carter, DC | 1 |
| Smyth, JF | 1 |
| Allan, SG | 1 |
| Kaye, SB | 1 |
| Sangster, G | 1 |
| Calman, KC | 1 |
| Hutcheon, AW | 1 |
| Wickramasinghe, SN | 1 |
| Aroney, RS | 1 |
| Levi, JA | 1 |
| Dalley, DN | 1 |
| Kalechman, Y | 1 |
| Rushkin, G | 1 |
| Nerubay, J | 1 |
| Albeck, M | 1 |
| Sredni, B | 1 |
| Mazza, P | 1 |
| Zinzani, PL | 1 |
| Martelli, M | 1 |
| Fiacchini, M | 1 |
| Bocchia, M | 1 |
| Pileri, S | 1 |
| Falini, B | 1 |
| Martelli, MF | 1 |
| Amadori, S | 2 |
| Papa, G | 2 |
| Colucci, G | 1 |
| Romito, S | 1 |
| Gebbia, V | 1 |
| Pacilio, G | 1 |
| Giotta, F | 1 |
| Testa, A | 1 |
| Pezzella, G | 1 |
| Durini, E | 1 |
| Agostara, B | 1 |
| Cariello, S | 1 |
| Budd, GT | 1 |
| Herzog, P | 1 |
| Bukowski, RM | 1 |
| Bellman, B | 1 |
| Gregory, NA | 1 |
| Silvers, D | 1 |
| Fountain, KS | 1 |
| Khlusov, IA | 1 |
| Dygaĭ, AM | 1 |
| Aksinenko, SG | 1 |
| Gol'dberg, ED | 1 |
| Rice, A | 1 |
| Barbot, C | 1 |
| Lacombe, F | 1 |
| Dubosc-Marchenay, N | 1 |
| Marit, G | 1 |
| Hau, F | 1 |
| Boiron, JM | 1 |
| Reiffers, J | 1 |
| Roman-Unfer, S | 1 |
| Bitran, JD | 1 |
| Garrison, L | 1 |
| Proeschel, C | 1 |
| Hanauer, S | 1 |
| Schroeder, L | 1 |
| Johnson, L | 1 |
| Klein, L | 1 |
| Martinec, J | 1 |
| Kovacs, CJ | 1 |
| Powell, DS | 1 |
| Evans, MJ | 1 |
| Thomas-Patterson, D | 1 |
| Johnke, RM | 1 |
| Hejna, M | 1 |
| Kornek, GV | 1 |
| Raderer, M | 1 |
| Valencak, J | 1 |
| Weinländer, G | 1 |
| Fiebiger, W | 1 |
| Miholic, J | 1 |
| Scheithauer, W | 1 |
| Rudolph, KL | 1 |
| Chang, S | 1 |
| Lee, HW | 1 |
| Blasco, M | 1 |
| Gottlieb, GJ | 1 |
| Greider, C | 1 |
| DePinho, RA | 1 |
| Banu, N | 1 |
| Deng, B | 1 |
| Lyman, SD | 1 |
| Avraham, H | 1 |
| Viens, P | 1 |
| Palangié, T | 1 |
| Janvier, M | 1 |
| Fabbro, M | 1 |
| Roché, H | 1 |
| Delozier, T | 1 |
| Labat, JP | 1 |
| Linassier, C | 1 |
| Audhuy, B | 1 |
| Feuilhade, F | 1 |
| Costa, B | 1 |
| Delva, R | 1 |
| Cure, H | 1 |
| Rousseau, F | 1 |
| Guillot, A | 1 |
| Mousseau, M | 1 |
| Ferrero, JM | 1 |
| Bardou, VJ | 1 |
| Jacquemier, J | 1 |
| Pouillart, P | 1 |
| Kimura, Y | 1 |
| Okuda, H | 1 |
| Meropol, NJ | 1 |
| Rustum, YM | 2 |
| Creaven, PJ | 1 |
| Blumenson, LE | 1 |
| Frank, C | 1 |
| Pospísil, M | 1 |
| Netíková, J | 1 |
| Znojil, V | 1 |
| Kozuch, P | 1 |
| Petryk, M | 1 |
| Bruckner, HW | 1 |
| Maisin, H | 1 |
| Anckaert, MA | 1 |
| Van Evercoren, A | 1 |
| De Coster, BM | 1 |
| Hopkins, HA | 1 |
| Looney, WB | 1 |
| Kane, RC | 1 |
| Cashdollar, MR | 1 |
| Bernath, AM | 1 |
| Ernst, H | 1 |
| Stolle, E | 1 |
| Weber, P | 1 |
| Scheffler, A | 1 |
| Riedel, B | 1 |
| Ingle, JN | 1 |
| Tormey, DC | 1 |
| Bull, JM | 1 |
| Simon, RM | 1 |
| Ogaard, S | 1 |
| Jensen, TS | 1 |
| Trainor, KJ | 1 |
| Morley, AA | 1 |
| Kelsen, D | 1 |
| Atiq, OT | 1 |
| Saltz, L | 1 |
| Niedzwiecki, D | 1 |
| Ginn, D | 1 |
| Chapman, D | 1 |
| Heelan, R | 1 |
| Lightdale, C | 1 |
| Vinciguerra, V | 1 |
| Brennan, M | 1 |
| Ishikawa, M | 1 |
| Kikuta, H | 1 |
| Imaizumi, A | 1 |
| Suzuki, E | 1 |
| Takayanagi, Y | 1 |
| Sasaki, K | 1 |
| Trump, DL | 1 |
| Egorin, MJ | 1 |
| Forrest, A | 1 |
| Willson, JK | 1 |
| Remick, S | 1 |
| Tutsch, KD | 1 |
| Legha, SS | 1 |
| Dimery, IW | 1 |
| Maeta, M | 1 |
| Koga, S | 1 |
| Yoshioka, H | 1 |
| Murakami, A | 1 |
| Wakatsuki, T | 1 |
| Becouarn, Y | 1 |
| Calabet, J | 1 |
| Brunet, R | 1 |
| Kish, JA | 1 |
| Ensley, JF | 1 |
| Jacobs, JR | 1 |
| Binns, P | 1 |
| al-Sarraf, M | 1 |
| Zhao, TP | 1 |
| He, GF | 1 |
| Arbuck, SG | 1 |
| Douglass, HO | 1 |
| Trave, F | 1 |
| Milliron, S | 1 |
| Baroni, M | 1 |
| Nava, H | 1 |
| Emrich, LJ | 1 |
| Marini, G | 1 |
| Simoncini, E | 1 |
| Zaniboni, A | 1 |
| Gorni, F | 1 |
| Marpicati, P | 1 |
| Zambruni, A | 1 |
| Guglielmi, C | 1 |
| Anselmo, AP | 1 |
| Baroni, CD | 1 |
| Biagini, C | 1 |
| Cimino, G | 1 |
| Mandelli, F | 1 |
| Boesen, EA | 1 |
| Moertel, CG | 1 |
| Ansfield, FJ | 1 |
| Carter, AC | 1 |
| Goldenberg, IS | 1 |
| Segaloff, A | 1 |
| Waxman, S | 1 |
| Herbert, V | 1 |
| Trial | Phase | Enrollment | Study Type | Start Date | Status | ||
|---|---|---|---|---|---|---|---|
| Randomized Controlled Trial of the Efficacy of Adjuvant Chemotherapy in Patients With Residual Lesions After Concurrent Radiochemotherapy for Locally Advanced Cervical Cancer[NCT04409860] | 120 participants (Anticipated) | Interventional | 2020-05-26 | Recruiting | |||
| [information is prepared from clinicaltrials.gov, extracted Sep-2024] | |||||||
5 reviews available for fluorouracil and Bone Marrow Diseases
| Article | Year |
|---|---|
Capecitabine-based combination therapy for breast cancer: implications for nurses.
Topics: Alopecia; Antimetabolites, Antineoplastic; Antineoplastic Combined Chemotherapy Protocols; Bone Marr | 2009 |
Complications of hepatic artery infusion: a review of 4580 reported cases.
Topics: Antimetabolites, Antineoplastic; Arterial Occlusive Diseases; Bone Marrow Diseases; Catheters, Indwe | 2001 |
The deoxyuridine suppression test: a review of its clinical and research applications.
Topics: Alcoholism; Anemia, Hemolytic; Anticonvulsants; Bone Marrow Cells; Bone Marrow Diseases; Cells; Deox | 1981 |
A comprehensive update on the use of chemotherapy for metastatic pancreatic adenocarcinoma.
Topics: Adenocarcinoma; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Bone Marrow D | 2002 |
Chemotherapy of bronchial carcinoma.
Topics: Animals; Antimetabolites; Antineoplastic Agents; Blood Cell Count; Bone Marrow Diseases; Bronchial N | 1973 |
11 trials available for fluorouracil and Bone Marrow Diseases
| Article | Year |
|---|---|
A study of weekly paclitaxel plus 5-fluorouracil and cisplatin for patients with advanced or recurrent inoperable gastric cancer.
Topics: Adenocarcinoma; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Bone Marrow Diseases; C | 2009 |
Concurrent mitomycin C, 5-fluorouracil, and radiotherapy in the treatment of locally advanced carcinoma of the cervix: a randomized trial.
Topics: Adenocarcinoma; Administration, Oral; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; B | 2003 |
Triple drug chemotherapy for advanced ovarian carcinoma: comparative study of two regimens.
Topics: Antineoplastic Agents; Bone Marrow Diseases; Carcinoma; Clinical Trials as Topic; Cyclophosphamide; | 1981 |
MACOP-B vs F-MACHOP regimen in the treatment of high-grade non-Hodgkin's lymphomas.
Topics: Adult; Antineoplastic Combined Chemotherapy Protocols; Bleomycin; Bone Marrow Diseases; Cyclophospha | 1995 |
Laevofolinic acid, 5-fluorouracil, cyclophosphamide and escalating doses of epirubicin with granulocyte colony-stimulating factor support in locally advanced and/or metastatic breast carcinoma: a phase I-II study of the Southern Italy Oncology Group (GOIM
Topics: Adult; Antineoplastic Combined Chemotherapy Protocols; Bone Marrow Diseases; Breast Neoplasms; Combi | 1995 |
Phase I/II trial of dipyridamole, 5-fluorouracil, leukovorin, and mitoxantrone in metastatic breast cancer.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Bone Marrow Diseases; Breast Neoplasms; | 1994 |
A phase II study of cyclophosphamide followed by PIXY321 as a means of mobilizing peripheral blood hematopoietic progenitor cells.
Topics: Adult; Antineoplastic Combined Chemotherapy Protocols; Blood Cells; Bone Marrow Diseases; Breast Neo | 1996 |
5-methyltetrahydrofolate for biochemical modulation of fluorouracil (FU) in patients with advanced colorectal cancer: a randomized phase I-II study of two different FU administration schedules.
Topics: Adenocarcinoma; Adult; Aged; Antimetabolites, Antineoplastic; Bone Marrow Diseases; Colorectal Neopl | 1998 |
First-line high-dose sequential chemotherapy with rG-CSF and repeated blood stem cell transplantation in untreated inflammatory breast cancer: toxicity and response (PEGASE 02 trial).
Topics: Adenocarcinoma; Adult; Antineoplastic Combined Chemotherapy Protocols; Blood Transfusion; Bone Marro | 1999 |
Phase I and pharmacokinetic study of weekly 5-fluorouracil administered with granulocyte-macrophage colony-stimulating factor and high-dose leucovorin: a potential role for growth factor as mucosal protectant.
Topics: Adult; Aged; Antidotes; Antimetabolites, Antineoplastic; Bone Marrow Diseases; Cohort Studies; Diarr | 1999 |
FAMTX versus etoposide, doxorubicin, and cisplatin: a random assignment trial in gastric cancer.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Bone Marrow Diseases; Cisplatin; Combin | 1992 |
46 other studies available for fluorouracil and Bone Marrow Diseases
| Article | Year |
|---|---|
High fat diet-induced obesity exacerbates hematopoiesis deficiency and cytopenia caused by 5-fluorouracil via peroxisome proliferator-activated receptor γ.
Topics: Animals; Bone Marrow; Bone Marrow Diseases; Dietary Fats; Flow Cytometry; Fluorouracil; Hematopoiesi | 2018 |
Overall survival of children and adolescents with mature B cell non-Hodgkin lymphoma who had refractory or relapsed disease during or after treatment with FAB/LMB 96: A report from the FAB/LMB 96 study group.
Topics: Adolescent; Antineoplastic Combined Chemotherapy Protocols; Bone Marrow Diseases; Carmustine; Child; | 2018 |
Myelotoxicity of carboplatin is increased in vivo in db/db mice, the animal model of obesity-associated diabetes mellitus.
Topics: Animals; Antineoplastic Agents; Bone Marrow Diseases; Carboplatin; Diabetes Mellitus, Experimental; | 2015 |
Echinacoside improves hematopoietic function in 5-FU-induced myelosuppression mice.
Topics: Animals; Blotting, Western; Bone Marrow Cells; Bone Marrow Diseases; Cell Proliferation; Colony-Form | 2015 |
Ash1l controls quiescence and self-renewal potential in hematopoietic stem cells.
Topics: Anemia, Aplastic; Animals; Animals, Newborn; Bone Marrow Diseases; Bone Marrow Failure Disorders; Bo | 2015 |
Clinical Study on Lobaplatin Combined with 5-Fu and Concurrent Radiotherapy in Treating Patients with Inoperable Esophageal Cancer.
Topics: Aged; Antineoplastic Combined Chemotherapy Protocols; Bone Marrow Diseases; Carcinoma, Squamous Cell | 2015 |
Long-Term Bone Marrow Suppression During Postoperative Chemotherapy in Rectal Cancer Patients After Preoperative Chemoradiation Therapy.
Topics: Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Bone Marrow; Bone Marrow Dise | 2016 |
Weekly Multi-agent Chemotherapy (CMF-b) for Advanced Non-melanoma Skin Cancer.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Bleomycin; Bone Marr | 2016 |
Interleukin 1 receptor antagonist inhibits normal hematopoiesis and reduces lethality and bone marrow toxicity of 5-fluouracil in mouse.
Topics: Animals; Antimetabolites, Antineoplastic; Blood Cell Count; Blood Platelets; Bone Marrow Cells; Bone | 2009 |
Comparison of alternate-day versus consecutive-day treatment with S-1: assessment of tumor growth inhibition and toxicity reduction in gastric cancer cell lines in vitro and in vivo.
Topics: Animals; Antimetabolites, Antineoplastic; Apoptosis; Bone Marrow Diseases; Cell Proliferation; Drug | 2008 |
Induction of apoptosis of azurin synthesized from P. aeruginosa MTCC 2453 against Dalton's lymphoma ascites model.
Topics: Animals; Antimetabolites, Antineoplastic; Antineoplastic Agents; Apoptosis; Apoptosis Regulatory Pro | 2011 |
[Role of pharmacokinetic monitoring of serum fluorouracil concentration in patients with local advanced and metastatic colorectal cancer and further improving efficacy of fluorouracil-based chemotherapy].
Topics: Adenocarcinoma; Adenocarcinoma, Mucinous; Adult; Aged; Antineoplastic Combined Chemotherapy Protocol | 2012 |
Effect of rosiglitazone, an insulin sensitizer, on myelotoxicity caused by repeated doses of 5-fluorouracil.
Topics: Animals; Antimetabolites, Antineoplastic; Bone Marrow Diseases; Bone Regeneration; Female; Fluoroura | 2006 |
Peroral IMUNOR, a low-molecular-weight immunomodulator prepared from disintegrated and ultrafiltered leukocytes, enhances recovery from myelosuppression induced by cisplatin or 5-fluorouracil.
Topics: Animals; Antimetabolites, Antineoplastic; Antineoplastic Agents; Bone Marrow Cells; Bone Marrow Dise | 2006 |
Myelophil, a mixture of Astragali Radix and Salviae Radix extract, moderates toxic side effects of fluorouracil in mice.
Topics: Animals; Antimetabolites, Antineoplastic; Behavior, Animal; Bone Marrow; Bone Marrow Diseases; Cell | 2008 |
Advanced minimal residual ovarian carcinoma: abdominopelvic irradiation following combination chemotherapy.
Topics: Adenocarcinoma; Adult; Aged; Altretamine; Antineoplastic Agents; Antineoplastic Combined Chemotherap | 1983 |
Advanced gastric cancer: experience in Scotland using 5-fluorouracil, adriamycin and mitomycin-C.
Topics: Adenocarcinoma; Antineoplastic Combined Chemotherapy Protocols; Bone Marrow Diseases; Doxorubicin; D | 1984 |
Effect of the immunomodulator AS101 on chemotherapy-induced multilineage myelosuppression, thrombocytopenia, and anemia in mice.
Topics: Adjuvants, Immunologic; Anemia; Animals; Antineoplastic Agents; Bone Marrow Diseases; Cells, Culture | 1995 |
Sweat gland carcinoma with metastases to the skin: response to 5-fluorouracil chemotherapy.
Topics: Aged; Bone Marrow Diseases; Bone Neoplasms; Carcinoma, Signet Ring Cell; Facial Neoplasms; Fluoroura | 1995 |
[Significance of sympathetic-adrenal structures in hematopoiesis regulation in cytostatic myelodepression].
Topics: Adrenal Glands; Animals; Bone Marrow Diseases; Cells, Cultured; Dihydroergotamine; Erythroid Precurs | 1993 |
5-fluorouracil permits access to a primitive subpopulation of peripheral blood stem cells.
Topics: Antineoplastic Agents; Blood Cells; Bone Marrow Diseases; Cell Cycle; Colony-Forming Units Assay; Cu | 1993 |
Enhanced platelet recovery in myelosuppressed mice treated with interleukin-1 and macrophage colony-stimulating factor: potential interactions with cytokines having megakaryocyte colony-stimulating activity.
Topics: Animals; Bone Marrow Diseases; Colony-Stimulating Factors; Cytokines; Drug Interactions; Female; Flu | 1996 |
Longevity, stress response, and cancer in aging telomerase-deficient mice.
Topics: Aging; Alopecia; Animals; Body Weight; Bone Marrow Diseases; Fluorouracil; Hair Color; Longevity; Mi | 1999 |
Modulation of haematopoietic progenitor development by FLT-3 ligand.
Topics: Animals; Bone Marrow Diseases; Cell Lineage; Cells, Cultured; Colony-Forming Units Assay; Enzyme Ind | 1999 |
Prevention by carp extract of myelotoxicity and gastrointestinal toxicity induced by 5-fluorouracil without loss of antitumor activity in mice.
Topics: Amino Acids; Animals; Antimetabolites, Antineoplastic; Bone Marrow Diseases; Carps; Chemical and Dru | 1999 |
Drugs elevating extracellular adenosine enhance cell cycling of hematopoietic progenitor cells as inferred from the cytotoxic effects of 5-fluorouracil.
Topics: Adenosine; Adenosine Monophosphate; Animals; Antimetabolites, Antineoplastic; Bone Marrow Diseases; | 2001 |
[Combination of chemotherapy and radiotherapy. II. Differential effect on the medullary syndrome of irradiation combined with the drug administered in fractional doses and at various times].
Topics: Animals; Bone Marrow Diseases; Drug Administration Schedule; Female; Fluorouracil; Lethal Dose 50; M | 1979 |
Synchronization of host and tumor responses for sequential therapy in experimental solid tumors.
Topics: Animals; Bone Marrow Diseases; Carcinoma, Hepatocellular; Cell Cycle; DNA, Neoplasm; Drug Administra | 1978 |
Treatment of advanced colorectal cancer with methyl-CCNU plus 5-day 5-fluorouracil infusion.
Topics: Adult; Aged; Bone Marrow Diseases; Carcinoembryonic Antigen; Colonic Neoplasms; Drug Therapy, Combin | 1978 |
[Preoperative radiotherapy of bladder cancer].
Topics: Bone Marrow Diseases; Colitis; Cystitis; Elementary Particles; Fluorouracil; Humans; Mitosis; Preope | 1975 |
Bone marrow involvement in breast cancer: effect on response and tolerance to combination chemotherapy.
Topics: Adult; Aged; Blood Cell Count; Blood Platelets; Bone Marrow Diseases; Breast Neoplasms; Cyclophospha | 1977 |
[Combination cytostatic chemotherapy of advanced metastatic cancer of the prostate. A preliminary uncontrolled study].
Topics: Aged; Antibiotics, Antineoplastic; Antineoplastic Agents; Bone Marrow Diseases; Cyclophosphamide; Dr | 1977 |
Screening of cytotoxic drugs for residual bone marrow damage.
Topics: Animals; Antineoplastic Agents; Bone Marrow; Bone Marrow Diseases; Busulfan; Carmustine; Cell Surviv | 1976 |
Sustained release of 5-fluorouracil from oil/water emulsions.
Topics: Animals; Bone Marrow Diseases; Delayed-Action Preparations; Emulsions; Fluorouracil; Mice; Oils; Wat | 1992 |
Pharmacokinetic and pharmacodynamic analysis of fluorouracil during 72-hour continuous infusion with and without dipyridamole.
Topics: Bone Marrow Diseases; Dipyridamole; Dose-Response Relationship, Drug; Drug Interactions; Fluorouraci | 1991 |
High-dose cisplatin administration without hypertonic saline: observation of disabling neurotoxicity.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Bone Marrow Diseases; Carcinoma, Squamo | 1985 |
Intra-hepato-arterial infusions of cis-diamminedichloroplatinum (II) and 5-fluorouracil clinically effective for malignant liver tumors.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Bone Marrow Diseases; Carcinoma, Hepato | 1985 |
Phase II study of a 5-fluorouracil, teniposide and mitomycin-C combination chemotherapy in advanced colorectal carcinomas.
Topics: Antineoplastic Combined Chemotherapy Protocols; Bone Marrow Diseases; Colonic Neoplasms; Diarrhea; D | 1988 |
Evaluation of high-dose cisplatin and 5-FU infusion as initial therapy in advanced head and neck cancer.
Topics: Antineoplastic Combined Chemotherapy Protocols; Bone Marrow Diseases; Carcinoma, Squamous Cell; Cisp | 1988 |
A phase II clinical trial of flutamide in the treatment of advanced breast cancer.
Topics: Antineoplastic Combined Chemotherapy Protocols; Bone Marrow Diseases; Breast Neoplasms; Cyclophospha | 1988 |
A phase II trial of 5-fluorouracil and high-dose intravenous leucovorin in gastric carcinoma.
Topics: Adenocarcinoma; Bone Marrow Diseases; Diarrhea; Drug Evaluation; Erythema; Fluorouracil; Humans; Inj | 1987 |
5-Fluorouracil and high-dose folinic acid as salvage treatment of advanced breast cancer: an update.
Topics: Antineoplastic Combined Chemotherapy Protocols; Bone Marrow Diseases; Breast Neoplasms; Drug Evaluat | 1987 |
Sequential combination chemotherapy of high-grade non-Hodgkin's lymphoma with 5-fluorouracil, methotrexate, cytosine-arabinoside, cyclophosphamide, doxorubicin, vincristine, and prednisone (F-MACHOP).
Topics: Adolescent; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Bone Marrow Diseases; Cyclo | 1987 |
Therapy of advanced gastrointestinal cancer with the nitrosoureas.
Topics: Adenocarcinoma; Antineoplastic Agents; Bone Marrow Diseases; Carmustine; Colonic Neoplasms; Cyclohex | 1973 |
Phase I study of phenesterin (NSC-104469).
Topics: Administration, Oral; Adult; Aged; Androgens; Antineoplastic Agents; Blood Cell Count; Blood Platele | 1971 |
Mechanism of pyrimethamine-induced megaloblastosis in human bone marrow.
Topics: Anemia, Macrocytic; Bone Marrow; Bone Marrow Diseases; Chorioretinitis; Culture Techniques; Deoxyuri | 1969 |